Search Results
Jul 24, 2026, 06:05 ET FLAGSTAR BANK REPORTS SECOND QUARTER 2026 NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.06 PER DILUTED SHARE AND ADJUSTED NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.05 PER DILUTED SHARE
billion or 29%Total MF/CRE exposure down $1.5 billion or 4%Wholesale borrowings, mainly FHLB advances, declined
More news about: Flagstar Bank, N.A.
Jun 29, 2026, 16:30 ET mF International Limited Filed 2025 Annual Report on Form 20-F
HONG KONG, June 29, 2026 /PRNewswire/ -- mF International Limited (NASDAQ:MFI) ("mF International" or the "Company") today announced that it has filed its annual report on Form
More news about: mF International Limited
Jun 26, 2026, 12:35 ET Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Dec;8(8):561-7.20 Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol. 2010 Oct;23(5):536-40.21 Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011; 2011:404101.22 Haliloglu G, et al. Gender
More news about: Johnson & Johnson
Jun 19, 2026, 07:03 ET BSE Index Services launches BSE Saatvik 100 Index
philosophy."This new index can be used for running passive strategies such as ETFs and Index Funds. It can also be used for benchmarking of PMS strategies, MF schemes and fund portfolio. Investors can now access a broader spectrum of market opportunities, further enriching their investment strategies with this
More news about: BSE
Jun 17, 2026, 08:30 ET CME Group Terry Duffy Will Step Down as Chief Executive Officer and Transition to Executive Chairman of the Board in March 2027; President and CFO Lynne Fitzpatrick Will Be Appointed CEO
Exchange in 2008. He also guided the company through times of turbulence including the global financial crisis of 2008 and the downfall of trading firm MF Global. His long, proven track record of innovation continues and has included the 2018 acquisition of NEX, a landmark partnership with Google Cloud
More news about: CME Group
Jun 15, 2026, 17:58 ET 美納里尼集團於 2026 年歐洲血液學協會 (EHA) 年會公佈 Selinexor 聯合 Ruxolitinib 治療骨髓纖維化的第 3 期 SENTRY 試驗數據
Ergun 表示：「SENTRY 研究所顯示的強勁脾臟反應，以及令人鼓舞的早期總存活期數據，為受這種嚴重疾病困擾且預後欠佳的患者帶來了潛在新治療方案的希望。 我們致力為癌症患者帶來具變革性的治療方案，這份決心與承諾比以往任何時候都更堅定。」關於骨髓纖維化 (MF)骨髓纖維化 (MF) 是一種血癌，屬於一組稱為骨髓增殖性腫瘤 (Myeloproliferative Neoplasms，MPN) 的疾病。 這類疾病由骨髓內異常造血細胞過度增生所引起，並導致瘢痕組織形成。 有關瘢痕組織會妨礙身體製造健康血細胞。 骨髓纖維化屬罕見疾病，每 10 萬人當中每年僅約有一至兩人確診，而患者確診後的中位存活期為六年。
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 16:44 ET Le Groupe Menarini présente les résultats de l'essai clinique SENTRY de phase III sur l'association selinexor-ruxolitinib dans le traitement de la myélofibrose lors du congrès 2026 de l'Association européenne d'hématologie (EHA)
des traitements révolutionnaires aux patients atteints d'un cancer sont plus forts que jamais. »À propos de la myélofibrose (MF)La myélofibrose (MF) est un type de cancer du sang qui fait partie d'un groupe de maladies appelées néoplasmes myéloprolifératifs (NMP). Ces maladies sont
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:40 ET El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis
brindar tratamientos transformadores a los pacientes que enfrentan el cáncer es más firme que nunca".Acerca de mielofibrosis (MF)La mielofibrosis (MF) es un tipo de cáncer de sangre que pertenece a un grupo de enfermedades llamadas neoplasias mieloproliferativas (NMP). Estas enfermedades
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:00 ET Il Gruppo Menarini presenta i dati dello studio di fase 3 SENTRY su selinexor più ruxolitinib nella mielofibrosi in occasione del Congresso 2026 dell'Associazione Europea di Ematologia (EHA)
fornire trattamenti innovativi ai pazienti che affrontano il cancro sono più forti che mai".Informazioni sulla mielofibrosi (MF)La mielofibrosi (MF) è un tipo di tumore del sangue che appartiene a un gruppo di malattie denominate neoplasie mieloproliferative (MPN). Queste malattie
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 06:22 ET ROHM bringt ein neues Gehäuse mit Kühlung auf der Oberseite für SiC-MOSFETs auf den Markt, das eine hohe Wärmeableitung mit Hochspannungsfähigkeit verbindet
https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202606030283/_prw_PI1fl_Mf865kEu.jpg Bei xEVs erstreckt sich der Einsatz von SiC-Bauelementen mittlerweile nicht mehr nur auf Hauptwechselrichter,
More news about: ROHM Co., Ltd.
Jun 15, 2026, 01:26 ET Menarini Group、European Hematology Association (EHA)の2026年総会にて、骨髄線維症を対象としたセリネキソールとルキソリチニブの併用療法に関する第3相SENTRY試験のデータを発表
Leukemia & Lymphoma Society (LLS)。https://bloodcancerunited.org/blood-cancer/myeloproliferative-neoplasms-mpns/myelofibrosis-mf3. 骨髄線維症。Mayo Clinic。
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:17 ET 메나리니 그룹, 2026 유럽혈액학회(EHA) 학술대회에서 골수섬유증 대상 셀리넥서 및 룩소리티닙 병용요법의 제3상 SENTRY 시험 데이터 발표
골수 내 비정상 조혈세포의 과증식으로 인해 발생하며, 이는 흉터 조직 형성으로 이어진다. 이러한 섬유화는 신체가 건강한 혈액세포를 생성하기 어렵게 만든다. MF의 발생률은 10만 명당 매년 1~2명만 진단될 정도로 드물며, 진단 후 생존 기간 중앙값은 6년이다. 또한 MF 환자는 질환으로 인해 발생하는 피로, 비장 비대, 혈구 수 감소 등의 증상으로 삶의 질이 저하될 수 있다. 1,2,3의심되는 이상반응을 보고하려면 스템라인 테라퓨틱스(Stemline Therapeutics, Inc.)에
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
llevar tratamientos transformadores a los pacientes que enfrentan el cáncer es más fuerte que nunca".Acerca de la mielofibrosis (MF)La mielofibrosis (MF) es un tipo de cáncer de la sangre que pertenece a un grupo de enfermedades llamadas neoplasias mieloproliferativas (MPN). Estas enfermedades
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
em trazer tratamentos transformadores para pacientes que enfrentam câncer está mais forte do que nunca."Sobre mielofibrose (MF)A mielofibrose (MF) é um tipo de câncer no sangue que pertence a um grupo de doenças chamadas Neoplasias Mieloproliferativas (MPNs). Essas doenças são causadas
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:06 ET Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
mit Krebserkrankungen bahnbrechende Therapien zur Verfügung zu stellen, sind stärker denn je."Informationen zur Myelofibrose (MF)Myelofibrose (MF) ist eine Form von Blutkrebs, die zu einer Gruppe von Erkrankungen gehört, die als myeloproliferative Neoplasien (MPN) bezeichnet werden.
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
dedication and commitment to bring transformational treatments to patients facing cancer is stronger than ever."About Myelofibrosis (MF)Myelofibrosis (MF) is a type of blood cancer that belongs to a group of diseases called Myeloproliferative Neoplasms (MPNs). These diseases are caused by
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 10, 2026, 02:00 ET ROHM Launches New Top-side Cooling Package for SiC MOSFETs, Combining High Heat Dissipation with High Voltage Support
https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202606030283/_prw_PI1fl_Mf865kEu.jpg In xEVs, the adoption of SiC devices is expanding beyond main inverters to include power conversion
More news about: ROHM Co., Ltd.
Jun 10, 2026, 02:00 ET ROHM Launches New Top-side Cooling Package for SiC MOSFETs, Combining High Heat Dissipation with High Voltage Support
https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202606030283/_prw_PI1fl_Mf865kEu.jpg In xEVs, the adoption of SiC devices is expanding beyond main inverters to include power conversion
More news about: ROHM Co., Ltd.
Jun 02, 2026, 10:02 ET Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
JCO's website.About the Phase 3 SENTRY TrialSENTRY (XPORT-MF-034;
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 08:59 ET Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
JCO's website.About the Phase 3 SENTRY TrialSENTRY (XPORT-MF-034;
More news about: Karyopharm Therapeutics Inc.
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
PT, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro-Oncology. 2021;23(9):1447-1456.Mahajan A, Ahmed S, McAleer MF, et al. Prospective randomized trial of post-operative stereotactic radiosurgery versus observation for completely resected brain metastases. Lancet Oncol.
More news about: GT Medical Technologies
May 26, 2026, 17:12 ET 美納里尼集團於 2026 年美國臨床腫瘤學會 (ASCO) 年會上發佈新數據
Cancer Center) 癌症醫學部白血病科教授 Naveen Pemmaraju 醫學博士負責報告。 此外，Stemline 的合作夥伴 Karyopharm Therapeutics 將發表一項最新突破性口頭簡報，基於塞利尼索用於未接受過 JAK 抑制劑 (JAKi) 治療的骨髓纖維化 (MF) 患者的第 3 期 SENTRY 試驗。 塞利尼索在美國的市場推廣由 Karyopharm Therapeutics 負責，在歐盟則由 Stemline 負責。美納里尼集團行政總裁 Elcin Barker Ergun 表示：「我們即將發表的大量腫瘤學數據，涵蓋實體腫瘤及血液惡性腫瘤，展現我們決心應對最難治療且尚未滿足兼大量需求的癌症。
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 16:45 ET Menarini Group annuncia nuovi dati alla riunione annuale dell'American Society of Clinical Oncology (ASCO) 2026
di Stemline, terrà una presentazione orale con gli ultimi risultati dello studio di fase 3 SENTRY sul selinexor in pazienti affetti da mielofibrosi (MF) che non hanno mai ricevuto un trattamento con inibitori delle JAK. Selinexor è commercializzato negli Stati Uniti da Karyopharm Therapeutics e nell'UE
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
Karyopharm Therapeutics, presentará una presentación oral de última hora del ensayo SENTRY de fase 3 de selinexor en pacientes JAKi naïve con mielofibrosis (MF). Selinexor es comercializado en EE.UU. por Karyopharm Therapeutics y en la UE por Stemline."Los extensos datos oncológicos que se presentarán,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
Stemlines Partner, Karyopharm Therapeutics, einen aktuellen Vortrag über die Phase-3-Studie SENTRY mit Selinexor bei JAKi-naiven Patienten mit Myelofibrose (MF) halten. Selinexor wird in den USA von Karyopharm Therapeutics und in der EU von Stemline vermarktet.„Die umfangreichen Onkologiedaten, die präsentiert
More news about: Menarini Industrie Farmaceutiche Riunite